Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Chemogenetic tools to interrogate brain functions.

Sternson SM, Roth BL.

Annu Rev Neurosci. 2014;37:387-407. doi: 10.1146/annurev-neuro-071013-014048. Review.

PMID:
25002280
2.

DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.

Urban DJ, Roth BL.

Annu Rev Pharmacol Toxicol. 2015;55:399-417. doi: 10.1146/annurev-pharmtox-010814-124803. Review.

PMID:
25292433
3.

DREADDs for Neuroscientists.

Roth BL.

Neuron. 2016 Feb 17;89(4):683-94. doi: 10.1016/j.neuron.2016.01.040. Review.

PMID:
26889809
4.

The Use of DREADDs to Deconstruct Behavior.

Whissell PD, Tohyama S, Martin LJ.

Front Genet. 2016 May 17;7:70. doi: 10.3389/fgene.2016.00070. Review.

5.

G-protein-coupled designer receptors - new chemical-genetic tools for signal transduction research.

Thiel G, Kaufmann A, Rössler OG.

Biol Chem. 2013 Dec;394(12):1615-22. doi: 10.1515/hsz-2013-0164. Review.

PMID:
23893685
6.

Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms.

Wong M, Thompson TL, Moss RL.

Crit Rev Neurobiol. 1996;10(2):189-203. Review.

PMID:
8971129
7.

DREADD: a chemogenetic GPCR signaling platform.

Zhu H, Roth BL.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu007. doi: 10.1093/ijnp/pyu007.

8.

The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.

Chen X, Choo H, Huang XP, Yang X, Stone O, Roth BL, Jin J.

ACS Chem Neurosci. 2015 Mar 18;6(3):476-84. doi: 10.1021/cn500325v.

9.

Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution.

Pei Y, Dong S, Roth BL.

Curr Protoc Neurosci. 2010 Jan;Chapter 4:Unit 4.33. doi: 10.1002/0471142301.ns0433s50.

PMID:
20066658
10.

The coupling of neurotransmitter receptors to ion channels in the brain.

Nicoll RA.

Science. 1988 Jul 29;241(4865):545-51. Review.

PMID:
2456612
11.

Engineered GPCRs as tools to modulate signal transduction.

Pei Y, Rogan SC, Yan F, Roth BL.

Physiology (Bethesda). 2008 Dec;23:313-21. doi: 10.1152/physiol.00025.2008. Review.

12.

Genetically-encoded molecular probes to study G protein-coupled receptors.

Naganathan S, Grunbeck A, Tian H, Huber T, Sakmar TP.

J Vis Exp. 2013 Sep 13;(79). doi: 10.3791/50588.

13.
14.

Remote control of neuronal signaling.

Rogan SC, Roth BL.

Pharmacol Rev. 2011 Jun;63(2):291-315. doi: 10.1124/pr.110.003020. Review.

15.

Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.

Burnett CJ, Krashes MJ.

J Neurosci. 2016 Sep 7;36(36):9268-82. doi: 10.1523/JNEUROSCI.1333-16.2016.

PMID:
27605603
16.

Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs.

Dong S, Rogan SC, Roth BL.

Nat Protoc. 2010 Mar;5(3):561-73. doi: 10.1038/nprot.2009.239.

PMID:
20203671
17.

Unparalleled control of neural activity using orthogonal pharmacogenetics.

Shapiro MG, Frazier SJ, Lester HA.

ACS Chem Neurosci. 2012 Aug 15;3(8):619-29. doi: 10.1021/cn300053q. Review.

18.

DREADDs in Drosophila: a pharmacogenetic approach for controlling behavior, neuronal signaling, and physiology in the fly.

Becnel J, Johnson O, Majeed ZR, Tran V, Yu B, Roth BL, Cooper RL, Kerut EK, Nichols CD.

Cell Rep. 2013 Sep 12;4(5):1049-59. doi: 10.1016/j.celrep.2013.08.003.

19.
20.

A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior.

Vardy E, Robinson JE, Li C, Olsen RH, DiBerto JF, Giguere PM, Sassano FM, Huang XP, Zhu H, Urban DJ, White KL, Rittiner JE, Crowley NA, Pleil KE, Mazzone CM, Mosier PD, Song J, Kash TL, Malanga CJ, Krashes MJ, Roth BL.

Neuron. 2015 May 20;86(4):936-46. doi: 10.1016/j.neuron.2015.03.065.

Items per page

Supplemental Content

Support Center